Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Pixium Vision (PAR: PIX)

Last close As at 01/11/2024

EUR0.15

▲ −0.04 (−21.05%)

Market capitalisation

EUR1m

Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for Dry-ARMD. The company has completed a human feasibility study for Prima in Europe and expects to start implantations in a US feasibility study in H119.

Latest Insights

View More

Healthcare | Flash note

Pixium Vision — Safeguard proceedings underway

Healthcare | Update

Pixium Vision — Shareholder loan extends runway

Healthcare | Update

Pixium Vision — Focusing on reaching the PRIMAvera milestone

Healthcare | Flash note

Pixium Vision — Breakthrough designation provides validation
Pixium-Vision_resized
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (€m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (6.9) (92.8) (97.1)
Relative (13.0) (92.8) (97.3)
52 week high/low €0.2/€0.0

Financials

Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX) and Treatt (TET). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via website

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 2.7 (9.7) (10.9) (23.06) N/A N/A
2022A 2.0 (11.5) (10.3) (21.09) N/A N/A
2023E N/A N/A N/A N/A N/A N/A
2024E N/A N/A N/A N/A N/A N/A

Research

Update

Healthcare

Pixium Vision — Shareholder loan extends runway
Pixium-Vision_resized

Update

Healthcare

Pixium Vision — Focusing on reaching the PRIMAvera milestone
Pixium-Vision_resized

Healthcare

Flash note

Pixium Vision — Safeguard proceedings underway

Pixium-Vision_resized

Flash note

Healthcare

Pixium Vision — Breakthrough designation provides validation
Pixium-Vision_resized

Flash note

Healthcare

Pixium Vision — End of ESGO arrangement comes as no surprise
Pixium-Vision_resized

Flash note

Healthcare

Pixium Vision — Next-generation implant chip highlighted

Update

Healthcare

Pixium Vision — PRIMAvera implantations now completed

Flash note

Healthcare

Pixium Vision — PRIMAvera reaches full enrolment

Flash note

Healthcare

Pixium Vision — First Prima implantation in Italy

Flash note

Healthcare

Pixium Vision — Remote rehabilitation system approved

Update

Healthcare

Pixium Vision — ESGO financing deal shores up balance sheet
View All

Further insights

insight

Healthcare

Retinal implants

Thematics

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free